Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.
Blood|January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AMLRichard Dillon, Robert Hills, Sylvie Freeman, et al.
Leukemia|August 9, 2023
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Nicola Potter, Katya Mokretar, et al.
Blood Neoplasia|June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
Pageof 3